Given the global impact of COVID-19 and Japanese government recommendations, BIO has made the difficult decision to cancel the 2020 BIO Asia conference in Tokyo, scheduled to take place March 10-11, 2020.
Notifications have been sent to conference delegates, sponsors and speakers. If you have specific questions please contact firstname.lastname@example.org.
The health and safety of our attendees is of utmost concern and BIO is exercising an abundance of caution. Our mission is to advance biotechnology innovation by fostering collaboration, both locally and globally. All of our efforts are needed to conquer the emerging threat of COVID-19.
BIO looks forward to returning to Japan, March 9-10, 2021. View full press release.
(as of February 21, 2020)
- Experience two-days of partnering meetings with international biotech executives and investors.
- Gain insights into the challenges and opportunities policy leaders foresee for the Japanese biotech market and throughout the region.
- Facilitate connections with partners looking to invest, partner, or license in or out in your therapeutic area.
Assets by Therapeutic Area
Gynecology and obstetrics
|Increase Since Last Update
*as of February 14, 2020
Meet the venture capital and private equity investors focused on cross-border biotechnology development who are currently active in the partnering system and ready to meet.
Aceras Life Sciences | Asset Management Ventures | BioInnovation Capital | Chaperone Investment | Eight Roads Ventures | Japan First Republic Bank | Hannol Ventures | Harbin Pharma | JAFCO Mitsubishi UFJ Capital | Mitsui Global Investment | Momentum Biotech | MSQ Ventures | Otsuka Pharmacautical Co. | Premir Partners | Shinsei Capital Partners | W Global Capital